Mast cell tumors (MCTs) are hematopoietic neoplasms composed of mast cells. It is highly common in dogs and is extremely important in the veterinary oncology field. It represents the third most common tumor subtype, and is the most common malignant skin tumor in dogs, corresponding to 11% of skin cancer cases. The objective of this critical review was to present the report of the 2nd Consensus meeting on the Diagnosis, Prognosis, and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors, which was organized by the Brazilian Association of Veterinary Oncology (ABROVET) in August 2021. The most recent information on cutaneous and subcutaneous mast cell tumors in dogs is presented and discussed.

Clinical and Surgical Oncology E Veterinary Specialties São Paulo 04078 012 Brazil

Clinical and Surgical Oncology Vet Cancer Animal Oncology and Pathology São Paulo 04523 013 Brazil

Clinical Oncology and Radiation Therapy Oncopet Veterinary Rio de Janeiro 22631 000 Brazil

Clinical Oncology Onccarevet e Onconnectionvet Ribeirão Preto 14026 587 Brasil

Clinical Surgical and Palliative Care Oncology Onco Cane Veterinary São Paulo 04084 002 Brazil

Department of Animal Medicine Veterinary School Universidade Federal do Rio Grande do Sul Porto Alegre 91540 000 Brazil

Department of Pathology School of Veterinary Medicine and Animal Science Universidade de São Paulo São Paulo 05508 900 Brazil

Department of Surgery Medical Sciences College Universidade Estadual de Campinas Campinas 13083 970 Brazil

Department of Surgery School of Veterinary Medicine and Animal Science Universidade de São Paulo São Paulo 05508 270 Brazil

Department of Veterinary Clinic and Surgery Universidade Estadual Paulista Jaboticabal 14884 900 Brazil

Department of Veterinary Clinic School of Veterinary Science and Animal Health Universidade Estadual Paulista Botucatu 18618 681 Brazil

Department of Veterinary Medicine and Surgery Veterinary School Universidade Federal de Minas Gerais Belo Horizonte 31270 901 Brazil

Department of Veterinary Medicine Universidade Federal do Paraná Curitiba 80035 050 Brazil

Department of Veterinary Surgery and Animal Reproduction Universidade Estadual Paulista Botucatu 18618 681 Brazil

Eletro Onkovet Service Franca 14406 005 Brazil

General Pathology Department Dental School Universidade de São Paulo São Paulo 05508 000 Brazil

Histopathological Diagnosis Department VETPAT Animal Pathology and Molecular Biology Campinas 13073 022 Brazil

Institute of Health Sciences Universidade Paulista Bauru 17048 290 Brazil

Institute of Health Sciences Universidade Paulista São Paulo 01533 000 Brazil

Laboratory of Comparative and Translational Oncology Pirassununga 13635 900 Brazil

Naya Specialties Campo Belo 04608 003 Brazil

ONE Patologia Veterinária Santos 11055 051 Brazil

Radiation Oncology Service Pet Care Oncologic Center São Paulo 05659 010 Brazil

School of Veterinary Universidade Federal de Minas Gerais Belo Horizonte 31270 901 Brazil

SEOVET Specialized Service in Veterinary Oncology Clinical and Surgical Oncology São Paulo 05016 000 Brazil

Small Animal Internal Medicine Department School of Veterinary Medicine Universidade Metropolitana de Santos Santos 11045 002 Brazil

Surgery Department Univet Veterinary Clinic São José Do Rio Preto São José do Rio Preto 15085 420 Brazil

Surgical and Clinical Oncology Bota Fogo Veterinary Hospital Rio de Janeiro 22281 180 Brazil

Surgical Pathology Vet Câncer LTDA ME São Paulo 04523 013 Brazil

Técnica Cirúrgica da Pontifícia Pontifícia Universidade Católica do Paraná Curitiba 80215 901 Brazil

Veterinary Research Institute 621 00 Brno Czech Republic

Vetschool São Paulo Veterinária Universidade Estadual Paulista São Paulo 03308 010 Brazil

Zobrazit více v PubMed

Macy D.W. Canine Mast Cell Tumors. Vet. Clin. North Am. Small Anim. Pr. 1985;15:783–803. doi: 10.1016/S0195-5616(85)50036-4. PubMed DOI

Pakhrin B., Kang M.-S., Bae I.-H., Park M.-S., Jee H., You M.-H., Kim J.-H., Yoon B.-I., Choi Y.-K., Kim D.-Y. Retrospective study of canine cutaneous tumors in Korea. J. Vet. Sci. 2007;8:229–236. doi: 10.4142/jvs.2007.8.3.229. PubMed DOI PMC

Gamlem H., Nordstoga K., Glattre E. Canine neoplasia—Introductory paper. APMIS. 2008;116:5–18. doi: 10.1111/j.1600-0463.2008.125m2.x. PubMed DOI

Grabarević Ž., Bubić Špoljar J., Gudan Kurilj A., Šoštarić-Zuckermann I.C., Artuković B., Hohšteter M., Beck A., Džaja P., Maltar Strmečki N. Mast cell tumor in dogs–incidence and histopathological characterization. Coll. Antropol. 2009;33:253–258. PubMed

Villamil J.A., Henry C.J., Bryan J.N., Ellersieck M., Schultz L., Tyler J.W., Hahn A.W. Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms. J. Am. Vet. Med. Assoc. 2011;239:960–965. doi: 10.2460/javma.239.7.960. PubMed DOI

Kimura K.C., Gárate A.P., Dagli M.L.Z. Retrospective Study of Neoplasms in Domestic Animals: A Survey Between 1993 and 2002 of the Service of Animal Pathology Department of Pathology School of Veterinary Medicine and Animal Science University of Sao Paulo Southeast Brazil. Braz. J. Vet. Pathol. 2012;5:60–69.

Warland J., Dobson J.M. Breed predispositions in canine mast cell tumour: A single centre experience in the United Kingdom. Vet. J. 2013;197:496–498. doi: 10.1016/j.tvjl.2013.02.017. PubMed DOI

Freeman K., Kirtz G., Hooijberg E.H., Sick K., Leidinger E.F. Breed related odds ratio and anatomic distribution of canine mast cell tumours in Austria. Tierarztl. Prax. Ausg. K. 2014;42:367–373. doi: 10.15654/TPK-140165. PubMed DOI

Shoop-Worrall S., Marlow S., Church D.B., English K., McGreevy P.D., Stell A.J., Thomson P.C., O’Neill D.G., Brodbelt D.C. Prevalence and risk factors for mast cell tumours in dogs in England. Canine Genet. Epidemiol. 2015;2:1–10. doi: 10.1186/2052-6687-2-1. PubMed DOI PMC

Baioni E., Scanziani E., Vincenti M.C., Leschiera M., Bozzetta E., Pezzolato M., Desiato R., Bertolini S., Maurella C., Ru G. Estimating canine cancer incidence: Findings from a population-based tumour registry in northwestern Italy. BMC Vet. Res. 2017;13:1–9. doi: 10.1186/s12917-017-1126-0. PubMed DOI PMC

Horta R.S., LaValle G.E., Monteiro L.N., Souza M.C.C., Cassali G.D., Araújo R.B. Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features. Vet. Pathol. 2018;55:212–223. doi: 10.1177/0300985817747325. PubMed DOI

Graf R., Pospischil A., Guscetti F., Meier D., Welle M., Dettwiler M. Cutaneous Tumors in Swiss Dogs: Retrospective Data From the Swiss Canine Cancer Registry, 2008–2013. Vet. Pathol. 2018;55:809–820. doi: 10.1177/0300985818789466. PubMed DOI

Kok M.K., Chambers J., Tsuboi M., Nishimura R., Tsujimoto H., Uchida K., Nakayama H. Retrospective study of canine cutaneous tumors in Japan, 2008-2017. J. Vet. Med. Sci. 2019;81:1133–1143. doi: 10.1292/jvms.19-0248. PubMed DOI PMC

De Nardi A.B., Costa M.T., Amorim R.L., Vasconcelos R.O., Dagli M.L.Z., Rocha N.S., Neto R.T., Grandi F., Alessi A.C., Magalhães G.M., et al. Brazilian Consensus For The Diagnosis, Treatment And Prognosis Of Cutaneous Mast Cell Tumors In Dogs. Investigação. 2018;17:1–15. doi: 10.26843/investigacao.v17i1.1837. DOI

Thamm D.H. Miscellaneous tumors: Hemangiosarcoma. In: Withrow S.J., Vail D.M., Page R.L., editors. Withrow and MacEwen’s Small Animal Clinical Oncology. 5th ed. Elsevier Saunders; St. Louis, MI, USA: 2013. pp. 679–688.

De Nardi A.B., Rodaski S., Sousa R.S., Costa T.A., Macedo T.R., Rodigheri S.M., Ríos A., Piekarz C.H. Prevalência de neoplasias e modalidades de tratamentos em cães, atendidos no hospital veterinário da Universidade federal do Paraná. Arch. Vet. Sci. 2002;7 doi: 10.5380/avs.v7i2.3977. DOI

De Souza T.M., Fighera R.A., Irigoyen L.F., De Barros C.S.L. Estudo retrospectivo de 761 tumores cutâneos em cães. CiÊNcia Rural. 2006;36:555–560. doi: 10.1590/S0103-84782006000200030. DOI

Meirelles A.E.W.B., Oliveira E.C., Rodrigues B.A., Costa G.R., Sonne L., Tesser E.S., Driemeier D. Prevalência de neoplasmas cutâneos em cães da região metropolitana de Porto Alegre, RS: 1.017 casos (2002–2007) Pesqui. Vet. Bras. 2010;30:968–973. doi: 10.1590/S0100-736X2010001100011. DOI

Kiupel M., Webster J.D., Miller R.A., Kaneene J.B. Impact of Tumour Depth, Tumour Location and Multiple Synchronous Masses on the Prognosis of Canine Cutaneous Mast Cell Tumours. J. Vet. Med. Ser. A. 2005;52:280–286. doi: 10.1111/j.1439-0442.2005.00726.x. PubMed DOI

Murphy S., Sparkes A.H., Blunden A.S., Brearley M.J., Smith K.C. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Vet. Rec. 2006;158:287–291. doi: 10.1136/vr.158.9.287. PubMed DOI

Mullins M.N., Dernell W.S., Withrow S.J., Ehrhart E.J., Thamm D.H., Lana S.E. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998–2004) J. Am. Vet. Med. Assoc. 2006;228:91–95. doi: 10.2460/javma.228.1.91. PubMed DOI

Costa-Casagrande T.A., Elias D.S., Melo S.R., Matera J.M. ESTUDO RETROSPECTIVO DO MASTOCITOMA CANINO NO SERVIÇO DE CIRURGIA DE PEQUENOS ANIMAIS—HOSPITAL VETERINÁRIO DA FACULDADE DE MEDICINA VETERINÁRIA E ZOOTECNIA DA UNIVERSIDADE DE SÃO PAULO. Arch. Vet. Sci. 2008;13 doi: 10.5380/avs.v13i3.11667. DOI

Furlani J.M., Daleck C.R., Vicenti F.A.M., De Nardi A.B., Pereira G.T., Santana Á.E., Eurides D., da Silva L.A.F. Mastocitoma canino: Estudo retrospectivo. CiÊNcia Anim. Bras. 2008;9:242–250.

Mochizuki H., Motsinger-Reif A., Bettini C., Moroff S., Breen M. Association of breed and histopathological grade in canine mast cell tumours. Vet. Comp. Oncol. 2016;15:829–839. doi: 10.1111/vco.12225. PubMed DOI

Śmiech A., Ślaska B., Łopuszyński W., Jasik A., Bochyńska D., Dąbrowski R. Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification. Acta Vet. Scand. 2018;60:1–9. doi: 10.1186/s13028-018-0424-2. PubMed DOI PMC

Pierini A., Lubas G., Gori E., Binanti D., Millanta F., Marchetti V. Epidemiology of Breed-Related Mast Cell Tumour Occurrence and Prognostic Significance of Clinical Features in a Defined Population of Dogs in West-Central Italy. Vet. Sci. 2019;6:53. doi: 10.3390/vetsci6020053. PubMed DOI PMC

Śmiech A., Łopuszyński W., Ślaska B., Bulak K., Jasik A. Occurrence and distribution of canine cutaneous mast cell tumour characteristics among predisposed breeds. J. Vet. Res. 2019;63:141–148. doi: 10.2478/jvetres-2019-0002. PubMed DOI PMC

London C., Galli S.J., Yuuki T., Hu Z.-Q., Helfand S.C., Geissler E.N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 1999;27:689–697. doi: 10.1016/S0301-472X(98)00075-7. PubMed DOI

Reguera M.J., Rabanal R.M., Puigdemont A., Ferrer L. Canine Mast Cell Tumors Express Stem Cell Factor Receptor. Am. J. Dermatopathol. 2000;22:49–54. doi: 10.1097/00000372-200002000-00010. PubMed DOI

Zemke D., Yamini B., Yuzbasiyan-Gurkan V. Mutations in the Juxtamembrane Domain of c-KIT Are Associated with Higher Grade Mast Cell Tumors in Dogs. Vet. Pathol. 2002;39:529–535. doi: 10.1354/vp.39-5-529. PubMed DOI

Turin L., Acocella F., Stefanello D., Oseliero A., Fondrini D., Brizzola S., Riva F. Expression of C-Kit Proto-Oncogene in Canine Mastocytoma: A Kinetic Study Using Real-Time Polymerase Chain Reaction. J. Vet. Diagn. Investig. 2006;18:343–349. doi: 10.1177/104063870601800404. PubMed DOI

Webster J.D., Yuzbasiyan-Gurkan V., Miller R.A., Kaneene J.B., Kiupel M. Cellular Proliferation in Canine Cutaneous Mast Cell Tumors: Associations with c-KIT and Its Role in Prognostication. Vet. Pathol. 2007;44:298–308. doi: 10.1354/vp.44-3-298. PubMed DOI

Ma Y., Longley B.J., Wang X., Blount J.L., Langley K., Caughey G.H. Clustering of Activating Mutations in c-KIT’s Juxtamembrane Coding Region in Canine Mast Cell Neoplasms. J. Investig. Dermatol. 1999;112:165–170. doi: 10.1046/j.1523-1747.1999.00488.x. PubMed DOI

Downing S., Chien M.B., Kass P.H., Moore P.F., London C.A. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c- kit in mast cell tumors of dogs. Am. J. Vet. Res. 2002;63:1718–1723. doi: 10.2460/ajvr.2002.63.1718. PubMed DOI

Webster J.D., Kiupel M., Yuzbasiyan-Gurkan V. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer. 2006;6:85–88. doi: 10.1186/1471-2407-6-85. PubMed DOI PMC

Webster J.D., Yuzbasiyan-Gurkan V., Kaneene J.B., Miller R., Resau J.H., Kiupel M. The Role of c-KIT in Tumorigenesis: Evaluation in Canine Cutaneous Mast Cell Tumors. Neoplasia. 2006;8:104–111. doi: 10.1593/neo.05622. PubMed DOI PMC

Letard S., Yang Y., Hanssens K., Palmérini F., Leventhal P.S., Guéry S., Moussy A., Kinet J.-P., Hermine O., Dubreuil P. Gain-of-Function Mutations in the Extracellular Domain of KIT Are Common in Canine Mast Cell Tumors. Mol. Cancer Res. 2008;6:1137–1145. doi: 10.1158/1541-7786.MCR-08-0067. PubMed DOI

London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., et al. Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision. Clin. Cancer Res. 2009;15:3856–3865. doi: 10.1158/1078-0432.CCR-08-1860. PubMed DOI

Takeuchi Y., Fujino Y., Watanabe M., Takahashi M., Nakagawa T., Takeuchi A., Bonkobara M., Kobayashi T., Ohno K., Uchida K., et al. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: A retrospective cohort study. Vet. J. 2013;196:492–498. doi: 10.1016/j.tvjl.2012.11.018. PubMed DOI

Tamlin V.S., Bottema C.D.K., Peaston A.E. Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment. Vet. Med. Sci. 2019;6:3–18. doi: 10.1002/vms3.201. PubMed DOI PMC

Vozdova M., Kubickova S., Fictum P., Fröhlich J., Jelinek F., Rubes J. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours. Vet. J. 2019;247:71–74. doi: 10.1016/j.tvjl.2019.03.005. PubMed DOI

Brocks B.A.W., Bertram C.A., Bartel A., Kirpensteijn J., Collins-Webb A., Catlin C., Thaiwong T., Kiupel M. Internal Tandem Duplication of Exon 8 of c-kit Is Associated With Longer Total Survival in Canine Cutaneous Mast Cell Tumors. Vet. Pathol. 2020;58:315–324. doi: 10.1177/0300985820973463. PubMed DOI

Kanaya N., Okuda M., Toyama N., Oikawa T., Inokuma H., Morimoto M., Hayashi T., Une S., Nakaichi M., Taura Y., et al. Detection of the Anti-P53 Antibodies in Dogs with Tumors. J. Vet. Med. Sci. 2002;64:973–979. doi: 10.1292/jvms.64.973. PubMed DOI

Zorzan E., Hanssens K., Giantin M., Dacasto M., Dubreuil P. Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors. PLoS ONE. 2015;10:e0142450. doi: 10.1371/journal.pone.0142450. PubMed DOI PMC

Yoda A., Adelmant G., Tamburini J., Chapuy B., Shindoh N., Yoda Y., Weigert O., Kopp N., Wu S.-C., Kim S.S., et al. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nat. Med. 2014;21:71–75. doi: 10.1038/nm.3751. PubMed DOI PMC

Mochizuki H., Thomas R., Moroff S., Breen M. Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade. Chromosom. Res. 2017;25:129–143. doi: 10.1007/s10577-016-9543-7. PubMed DOI

Jark P.C., Mundin D.B., de Carvalho M., Ferioli R.B., Anai L.A., Marchi F.A., Rogatto S.R., Laufer-Amorim R., Tinucci-Costa M. Genomic copy number variation associated with clinical outcome in canine cutaneous mast cell tumors. Res. Vet. Sci. 2017;111:26–30. doi: 10.1016/j.rvsc.2016.11.009. PubMed DOI

Patnaik A.K., Ehler W.J., MacEwen E.G. Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs. Vet. Pathol. 1984;21:469–474. doi: 10.1177/030098588402100503. PubMed DOI

Bostock D. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br. Vet. J. 1986;142:1–19. doi: 10.1016/0007-1935(86)90002-3. PubMed DOI

Weisse C., Shofer F.S., Sorenmo K. Recurrence Rates and Sites for Grade II Canine Cutaneous Mast Cell Tumors Following Complete Surgical Excision. J. Am. Anim. Hosp. Assoc. 2002;38:71–73. doi: 10.5326/0380071. PubMed DOI

Hume C.T., Kiupel M., Rigatti L., Shofer F.S., Skorupski K.A., Sorenmo K.U. Outcomes of Dogs with Grade 3 Mast Cell Tumors: 43 Cases (1997–2007) J. Am. Anim. Hosp. Assoc. 2011;47:37–44. doi: 10.5326/JAAHA-MS-5557. PubMed DOI

Daleck C.R., De Nardi A.B. Oncologia em cães e gatos. Volume 2. Grupo Gen-Editora Roca Ltda; Rio de Janeiro, Brazil: 2016. pp. 971–995.

O’Connell K., Thomson M. Evaluation of prognostic indicators in dogs with multiple, simultaneously occurring cutaneous mast cell tumours: 63 cases. Vet. Comp. Oncol. 2011;11:51–62. doi: 10.1111/j.1476-5829.2011.00301.x. PubMed DOI

Berlato D., Bulman-Fleming J., Clifford C.A., Garrett L., Intile J., Jones P., Kamstock D.A., Liptak J.M., Pavuk A., Powell R., et al. Value, Limitations, and Recommendations for Grading of Canine Cutaneous Mast Cell Tumors: A Consensus of the Oncology-Pathology Working Group. Vet. Pathol. 2021;58:858–863. doi: 10.1177/03009858211009785. PubMed DOI

Moore A.S., Frimberger A.E., Taylor D., Sullivan N. Retrospective outcome evaluation for dogs with surgically excised, solitary Kiupel high-grade, cutaneous mast cell tumours. Vet. Comp. Oncol. 2020;18:402–408. doi: 10.1111/vco.12565. PubMed DOI

Willmann M., Yuzbasiyan-Gurkan V., Marconato L., Dacasto M., Hadzijusufovic E., Hermine O., Sadovnik I., Gamperl S., Schneeweiss-Gleixner M., Gleixner K.V., et al. Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. Front. Vet. Sci. 2021;8 doi: 10.3389/fvets.2021.755258. PubMed DOI PMC

Macy D., Tams T. Canine Mast Cell Tumors. Vet. Clin. North Am. Small Anim. Pract. 1981;3:869–877. doi: 10.1016/S0195-5616(85)50036-4. PubMed DOI

Turrel J.M., Kitchell B.E., Miller L.M., Théon A. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. J. Am. Vet. Med. Assoc. 1988;193 PubMed

Fox L.E. Mast Cell Tumors. In: Morrison W.B., editor. Cancer in Dogs and Cats Medical and Surgical Management. Linppincott Williams & Wilkins; Philadelphia, PA, USA: 1998. pp. 479–488.

Nelson R., Couto C.G. Medicina interna de pequenos animais. Elsevier; Centro Rio de Janeiro, Brazil: 2015.

Sfiligoi G., Rassnick K.M., Scarlett J.M., Northrup N.C., Gieger T.L. Outcome of Dogs with Mast Cell Tumors in the Inguinal or Perineal Region Versus Other Cutaneous Locations: 124 Cases (1990–2001) J. Am. Vet. Med. Assoc. 2005;226:1368–1374. doi: 10.2460/javma.2005.226.1368. PubMed DOI

Hillman L.A., Garrett L.D., De Lorimier L.-P., Charney S.C., Borst L., Fan T.M. Biological behavior of oral and perioral mast cell tumors in dogs: 44 cases (1996–2006) J. Am. Vet. Med. Assoc. 2010;237:936–942. doi: 10.2460/javma.237.8.936. PubMed DOI

Stockham S.L., Basel D.L., Schmidt D.A. Mastocytemia in Dogs With Acute Inflammatory Diseases. Vet. Clin. Pathol. 1986;15:16–21. doi: 10.1111/j.1939-165X.1986.tb00862.x. PubMed DOI

Hikasa Y., Morita T., Futaoka Y., Sato K., Shimada A., Kagota K., Matsuda H. Connective Tissue-Type Mast Cell Leukemia in a Dog. J. Vet. Med. Sci. 2000;62:187–190. doi: 10.1292/jvms.62.187. PubMed DOI

Plier M.L., MacWilliams P.L. Schalm’s Veterinary Hematology. Vol. 5. Lippincott Williams & Wilkins; Philadelphia, PA, USA: 2000. pp. 747–754.

Welle M.M., Bley C.R., Howard J., Rüfenacht S. Canine mast cell tumours: A review of the pathogenesis, clinical features, pathology and treatment. Vet. Dermatol. 2008;19:321–339. doi: 10.1111/j.1365-3164.2008.00694.x. PubMed DOI

Blackwood L., Murphy S., Buracco P., De Vos J.P., De Fornel-Thibaud P., Hirschberger J., Kessler M., Pastor J., Ponce F., Savary-Bataille K., et al. European consensus document on mast cell tumours in dogs and cats. Vet. Comp. Oncol. 2012;10:e1–e29. doi: 10.1111/j.1476-5829.2012.00341.x. PubMed DOI

Takahashi T., Kadosawa T., Nagase M., Matsunaga S., Mochizuki M., Nishimura R., Sasaki N. Visceral mast cell tumors in dogs: 10 cases (1982-1997) J. Am. Vet. Med. Assoc. 2000;216:222–226. doi: 10.2460/javma.2000.216.222. PubMed DOI

Endicott M.M., Charney S.C., McKnight J.A., Loar A.S., Barger A.M., Bergman P.J. Clinicopathological findings and results of bone marrow aspiration in dogs with cutaneous mast cell tumours: 157 cases (1999?2002) Vet. Comp. Oncol. 2007;5:31–37. doi: 10.1111/j.1476-5829.2006.00115.x. PubMed DOI

Musser M., Berger E., Flaherty H.A., Fox L., Johannes C.M. Marked paraneoplastic hypereosinophilia associated with a low-grade, metastatic canine mast cell tumour. Vet. Rec. Case Rep. 2018;6:e000563. doi: 10.1136/vetreccr-2017-000563. DOI

Cifuentes-Arias S., Osorio-Morales L., Pedraza-Ordóñez F. Clinical follow-up of canine mast cell tumour cases diagnosed by cytology and histopathology. Vet. Stanica. 2021;52:397–403. doi: 10.46419/vs.52.4.1. DOI

Cowell R.L., Tyler R.D., Meinkoth J.H., DeNicola D.B. Diagnóstico citológico e hematologia de cães e gatos. Medvet. São Paulo. 2009:68–77.

De Strefezzi R.F., Xavier J.G., Kleeb S.R., Catão-Dias J.L. Nuclear Morphometry in Cytopathology: A Prognostic Indicator for Canine Cutaneous Mast Cell Tumors. J. Vet. Diagn. Investig. 2009;21:821–825. doi: 10.1177/104063870902100608. PubMed DOI

MacNeill A.L. Cytology of Canine and Feline Cutaneous and Subcutaneous Lesions and Lymph Nodes. Top. Companion Anim. Med. 2011;26:62–76. doi: 10.1053/j.tcam.2011.02.004. PubMed DOI

Grandi F., Beserra H.E.O., Costa L.D. Citopatologia veterinária diagnóstica. São Paulo: Medvet. 2014:80–90.

Camus M.S., Priest H.L., Koehler J.W., Driskell E.A., Rakich P.M., Ilha M.R., Krimer P.M. Cytologic Criteria for Mast Cell Tumor Grading in Dogs With Evaluation of Clinical Outcome. Vet. Pathol. 2016;53:1117–1123. doi: 10.1177/0300985816638721. PubMed DOI

Hergt F., Von Bomhard W., Kent M., Hirschberger J. Use of a 2-tier histologic grading system for canine cutaneous mast cell tumors on cytology specimens. Vet. Clin. Pathol. 2016;45:477–483. doi: 10.1111/vcp.12387. PubMed DOI

Bostock D.E. The prognosis following surgical removal of mastocytomas in dogs. J. Small Anim. Pr. 1973;14:27–40. doi: 10.1111/j.1748-5827.1973.tb06891.x. PubMed DOI

Preziosi R., Morini M., Sarli G. Expression of the KIT Protein (CD117) in Primary Cutaneous Mast Cell Tumors of the Dog. J. Vet. Diagn. Investig. 2004;16:554–561. doi: 10.1177/104063870401600610. PubMed DOI

Kiupel M., Webster J.D., Bailey K.L., Best S., DeLay J., Detrisac C.J., Fitzgerald S.D., Gamble D., Ginn P.E., Goldschmidt M.H., et al. Proposal of a 2-Tier Histologic Grading System for Canine Cutaneous Mast Cell Tumors to More Accurately Predict Biological Behavior. Vet. Pathol. 2010;48:147–155. doi: 10.1177/0300985810386469. PubMed DOI PMC

Thompson J.J., Pearl D.L., Yager J.A., Best S.J., Coomber B.L., Foster R.A. Canine Subcutaneous Mast Cell Tumor. Vet. Pathol. 2010;48:156–168. doi: 10.1177/0300985810387446. PubMed DOI

Fulcher R.P., Ludwig L.L., Bergman P.J., Newman S.J., Simpson A.M., Patnaik A.K. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. J. Am. Vet. Med. Assoc. 2006;228:210–215. doi: 10.2460/javma.228.2.210. PubMed DOI

Kamstock D.A., Ehrhart E.J., Getzy D.M., Bacon N.J., Rassnick K.M., Moroff S.D., Liu S.M., Straw R.C., McKnight C.A., Amorim R.L., et al. Recommended Guidelines for Submission, Trimming, Margin Evaluation, and Reporting of Tumor Biopsy Specimens in Veterinary Surgical Pathology. Vet. Pathol. 2010;48:19–31. doi: 10.1177/0300985810389316. PubMed DOI

Thompson J.J., Yager J.A., Best S.J., Pearl D.L., Coomber B.L., Torres R.N., Kiupel M., Foster R.A. Canine Subcutaneous Mast Cell Tumors. Vet. Pathol. 2010;48:169–181. doi: 10.1177/0300985810390716. PubMed DOI

Scarpa F., Sabattini S., Marconato L., Capitani O., Morini M., Bettini G. Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision. J. Am. Vet. Med. Assoc. 2012;240:1181–1187. doi: 10.2460/javma.240.10.1181. PubMed DOI

Sledge D.G., Webster J., Kiupel M. Canine cutaneous mast cell tumors: A combined clinical and pathologic approach to diagnosis, prognosis, and treatment selection. Vet. J. 2016;215:43–54. doi: 10.1016/j.tvjl.2016.06.003. PubMed DOI

Strefezzi R.D.F., Xavier J.G., Catão-Dias J.L. Morphometry of Canine Cutaneous Mast Cell Tumors. Vet. Pathol. 2003;40:268–275. doi: 10.1354/vp.40-3-268. PubMed DOI

Northrup N.C., Howerth E.W., Harmon B.G., Brown C.A., Carmicheal K.P., Garcia A.P., Latimer K.S., Munday J.S., Rakich P.M., Richey L.J., et al. Variation among Pathologists in the Histologic Grading of Canine Cutaneous Mast Cell Tumors with Uniform Use of a Single Grading Reference. J. Vet. Diagn. Investig. 2005;17:561–564. doi: 10.1177/104063870501700606. PubMed DOI

Pinczowski P., Torres-Neto R., Fabris V.E., Laufer-Amorim R. Mastocitoma cutâneo canino: Variação da graduação histopatológica entre patologistas. ClÍNica VeterinÁRia. 2008;77:76–78.

Shaw T., Kudnig S.T., Firestone S.M. Diagnostic accuracy of pre-treatment biopsy for grading cutaneous mast cell tumours in dogs. Vet. Comp. Oncol. 2017;16:214–219. doi: 10.1111/vco.12346. PubMed DOI

Meuten D.J., editor. Tumors in Domestic Animals. John Wiley & Sons; Hoboken, NJ, USA: 2020. p. 1008.

Romansik E.M., Reilly C.M., Kass P.H., Moore P.F., London C.A. Mitotic Index Is Predictive for Survival for Canine Cutaneous Mast Cell Tumors. Vet. Pathol. 2007;44:335–341. doi: 10.1354/vp.44-3-335. PubMed DOI

Elston L.B., Sueiro F.A., Cavalcanti J.N., Metze K. Letter to the Editor: The Importance of the Mitotic Index as a Prognostic Factor for Survival of Canine Cutaneous Mast Cell Tumors: A Validation Study. Vet. Pathol. 2009;46:362–364. doi: 10.1354/vp.46-2-362. PubMed DOI

Bertram C.A., Aubreville M., Gurtner C., Bartel A., Corner S.M., Dettwiler M., Kershaw O., Noland E.L., Schmidt A., Sledge D.G., et al. Computerized Calculation of Mitotic Count Distribution in Canine Cutaneous Mast Cell Tumor Sections: Mitotic Count Is Area Dependent. Vet. Pathol. 2019;57:214–226. doi: 10.1177/0300985819890686. PubMed DOI

Bertram C.A., Aubreville M., Donovan T.A., Bartel A., Wilm F., Marzahl C., Assenmacher C.-A., Becker K., Bennett M., Corner S., et al. Computer-assisted mitotic count using a deep learning–based algorithm improves interobserver reproducibility and accuracy. Vet. Pathol. 2021 doi: 10.1177/03009858211067478. PubMed DOI PMC

Newman S., Mrkonjich L., Walker K., Rohrbach B. Canine Subcutaneous Mast Cell Tumour: Diagnosis and Prognosis. J. Comp. Pathol. 2007;136:231–239. doi: 10.1016/j.jcpa.2007.02.003. PubMed DOI

Gill V., Leibman N., Monette S., Craft D.M., Bergman P.J. Prognostic Indicators and Clinical Outcome in Dogs with Subcutaneous Mast Cell Tumors Treated with Surgery Alone: 43 Cases. J. Am. Anim. Hosp. Assoc. 2020;56:215–225. doi: 10.5326/JAAHA-MS-6960. PubMed DOI

Weishaar K., Thamm D., Worley D., Kamstock D. Correlation of Nodal Mast Cells with Clinical Outcome in Dogs with Mast Cell Tumour and a Proposed Classification System for the Evaluation of Node Metastasis. J. Comp. Pathol. 2014;151:329–338. doi: 10.1016/j.jcpa.2014.07.004. PubMed DOI

Simoes J.P.C., Schoning P. Canine Mast Cell Tumors: A Comparison of Staining Techniques. J. Vet. Diagn. Investig. 1994;6:458–465. doi: 10.1177/104063879400600410. PubMed DOI

Hashmi A.A., Riaz R., Zia S., Shahid H., Malik U.A., Khan R., Irfan M., Shamail F., Zia F., Asif M.G. Impact of Histological Type and Grade on the Diagnostic Accuracy of Intraoperative Frozen Section for Detecting Breast Cancer Metastasis to Axillary Sentinel Lymph Nodes. Cureus. 2021;13 doi: 10.7759/cureus.16146. PubMed DOI PMC

Kaneko H., Deguchi M., Yano H. Submandibular lymph node metastasis of occult thyroid carcinoma first suspected to be a salivary gland tumor: A case report. J. Med. Case Rep. 2021;15:1–6. doi: 10.1186/s13256-021-02901-7. PubMed DOI PMC

Stern A. Frozen sections compared with paraffin-embedded sections: A retrospective veterinary autopsy study. Braz. J. Vet. Pathol. 2020;13 doi: 10.24070/bjvp.1983-0246.v13i1p12-16. DOI

Whitehair J.G., Griffey S.M., Olander H.J., Vasseur P.B., Naydan D. The Accuracy of Intraoperative Diagnoses Based on Examination of Frozen Sections A Prospective Comparison with Paraffin-Embedded Sections. Vet. Surg. 1993;22:255–259. doi: 10.1111/j.1532-950X.1993.tb00394.x. PubMed DOI

Puebla-Osorio N., Sarchio S.N.E., Ullrich S.E., Byrne S.N. Detection of Infiltrating Mast Cells Using a Modified Toluidine Blue Staining. Methods Mol. Biol. 2017;1627:213–222. doi: 10.1007/978-1-4939-7113-8_14. PubMed DOI

Abadie J.J., Amardeilh M.A., Delverdier M. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. J. Am. Vet. Med. Assoc. 1999;215 PubMed

Kiupel M., Webster J.D., Kaneene J.B., Miller R., Yuzbasiyan-Gurkan V. The Use of KIT and Tryptase Expression Patterns as Prognostic Tools for Canine Cutaneous Mast Cell Tumors. Vet. Pathol. 2004;41:371–377. doi: 10.1354/vp.41-4-371. PubMed DOI

Scase T.J., Edwards D., Miller J., Henley W., Smith K., Blunden A., Murphy S. Canine mast cell tumors: Correlation of apoptosis and proliferation markers with prognosis. J. Vet. Intern. Med. 2006;20:151–158. doi: 10.1111/j.1939-1676.2006.tb02835.x. PubMed DOI

Maglennon G.A., Murphy S., Adams V., Miller J., Smith K., Blunden A., Scase T.J. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours*. Vet. Comp. Oncol. 2008;6:268–274. doi: 10.1111/j.1476-5829.2008.00168.x. PubMed DOI

Strefezzi R.D.F., Kleeb S.R., Xavier J.G., Dias J.L.C. Avaliação da proliferação celular como indicador prognóstico para mastocitomas cutâneos caninos. Pesq. Vet. Bras. 2010;30:559–565. doi: 10.1590/S0100-736X2010000700009. DOI

Fonseca-Alves C.E., Palmieri C., Dagli M.L.Z., Laufer-Amorim R. Editorial: Precision Medicine in Veterinary Oncology. Front. Vet. Sci. 2021;8 doi: 10.3389/fvets.2021.718891. PubMed DOI PMC

Thompson J.J., Morrison J.A., Pearl D.L., Boston S.E., Wood G., Foster R.A., Coomber B.L. Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors. Vet. Pathol. 2015;53:545–558. doi: 10.1177/0300985815610388. PubMed DOI

Thamm D.H., Weishaar K.M., Charles J.B., Ehrhart E.J. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine. Vet. Comp. Oncol. 2019;18:169–175. doi: 10.1111/vco.12525. PubMed DOI

Smith J., Kiupel M., Farrelly J., Cohen R., Olmsted G., Kirpensteijn J., Brocks B., Post G. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone. Vet. Comp. Oncol. 2015;15:36–45. doi: 10.1111/vco.12140. PubMed DOI

Longley B., Reguera M.J., Ma Y. Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy. Leuk. Res. 2001;25:571–576. doi: 10.1016/S0145-2126(01)00028-5. PubMed DOI

Yamada O., Kobayashi M., Sugisaki O., Ishii N., Ito K., Kuroki S., Sasaki Y., Isotani M., Ono K., Washizu T., et al. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation. Vet. Immunol. Immunopathol. 2011;142:101–106. doi: 10.1016/j.vetimm.2011.04.002. PubMed DOI

Reguera M.J., Ferrer L., Rabanal R.M. Evaluation of an intron deletion in the c-kit gene of canine mast cell tumors. Am. J. Vet. Res. 2002;63:1257–1261. doi: 10.2460/ajvr.2002.63.1257. PubMed DOI

Cameron L.R.J., Grahn R.A., Chien M.B., Lyons L.A., London C.A. Detection of c-kit Mutations in Canine Mast Cell Tumors using Fluorescent Polyacrylamide Gel Electrophoresis. J. Vet. Diagn. Investig. 2004;16:95–100. doi: 10.1177/104063870401600201. PubMed DOI

Riva F., Brizzola S., Stefanello D., Crema S., Turin L. A Study of Mutations in the c-kit Gene of 32 Dogs with Mastocytoma. J. Vet. Diagn. Investig. 2005;17:385–388. doi: 10.1177/104063870501700416. PubMed DOI

Ohmori K., Kawarai S., Yasuda N., Tanaka A., Matsuda H., Nishimura R., Sasaki N., Tsujimoto H., Masuda K. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells. Vet. Immunol. Immunopathol. 2008;126:43–53. doi: 10.1016/j.vetimm.2008.06.014. PubMed DOI

Avery A.C. Molecular Diagnostics of Hematologic Malignancies in Small Animals. Vet. Clin. North Am. Small Anim. Pr. 2012;42:97–110. doi: 10.1016/j.cvsm.2011.11.001. PubMed DOI

Book A.P., Fidel J., Wills T., Bryan J., Sellon R., Mattoon J. CORRELATION OF ULTRASOUND FINDINGS, LIVER AND SPLEEN CYTOLOGY, AND PROGNOSIS IN THE CLINICAL STAGING OF HIGH METASTATIC RISK CANINE MAST CELL TUMORS. Vet. Radiol. Ultrasound. 2011;52:548–554. doi: 10.1111/j.1740-8261.2011.01839.x. PubMed DOI

Warland J., Amores-Fuster I., Newbury W., Brearley M., Dobson J.M. The utility of staging in canine mast cell tumours. Vet. Comp. Oncol. 2012;12:287–298. doi: 10.1111/vco.12012. PubMed DOI

Hughes J.R., Szladovits B., Drees R. Abdominal CT evaluation of the liver and spleen for staging mast cell tumors in dogs yields nonspecific results. Vet. Radiol. Ultrasound. 2019;60:306–315. doi: 10.1111/vru.12717. PubMed DOI

Tuohy J.L., Milgram J., Worley D.R., Dernell W.S. A review of sentinel lymph node evaluation and the need for its incorporation into veterinary oncology. Vet. Comp. Oncol. 2009;7:81–91. doi: 10.1111/j.1476-5829.2009.00183.x. PubMed DOI

Krick E.L., Billings A.P., Shofer F.S., Watanabe S., Sorenmo K.U. Cytological lymph node evaluation in dogs with mast cell tumours: Association with grade and survival*. Vet. Comp. Oncol. 2009;7:130–138. doi: 10.1111/j.1476-5829.2009.00185.x. PubMed DOI

Ku C., Kass P.H., Christopher M.M. Cytologic-histologic concordance in the diagnosis of neoplasia in canine and feline lymph nodes: A retrospective study of 367 cases. Vet. Comp. Oncol. 2016;15:1206–1217. doi: 10.1111/vco.12256. PubMed DOI

Ferrari R., Marconato L., Buracco P., Boracchi P., Giudice C., Iussich S., Grieco V., Chiti L.E., Favretto E., Stefanello D. The impact of extirpation of non-palpable/normal-sized regional lymph nodes on staging of canine cutaneous mast cell tumours: A multicentric retrospective study. Vet. Comp. Oncol. 2018;16:505–510. doi: 10.1111/vco.12408. PubMed DOI

Worley D.R. Incorporation of sentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures. Vet. Comp. Oncol. 2012;12:215–226. doi: 10.1111/j.1476-5829.2012.00354.x. PubMed DOI

Lapsley J., Hayes G.M., Janvier V., Newman A.W., Peters-Kennedy J., Balkman C., Sumner J.P., Johnson P. Influence of locoregional lymph node aspiration cytology vs sentinel lymph node mapping and biopsy on disease stage assignment in dogs with integumentary mast cell tumors. Vet. Surg. 2020;50:133–141. doi: 10.1111/vsu.13537. PubMed DOI

Fournier Q., Thierry F., Longo M., Malbon A., Cazzini P., Bisson J., Woods S., Liuti T., Bavcar S. Contrast-enhanced ultrasound for sentinel lymph node mapping in the routine staging of canine mast cell tumours: A feasibility study. Vet. Comp. Oncol. 2020;19:451–462. doi: 10.1111/vco.12647. PubMed DOI

Stefanello D., Buracco P., Sabattini S., Finotello R., Giudice C., Grieco V., Iussich S., Tursi M., Scase T., Di Palma S., et al. Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009–2014) J. Am. Vet. Med. Assoc. 2015;246:765–769. doi: 10.2460/javma.246.7.765. PubMed DOI

London C.A., Seguin B. Mast cell tumors in the dog. Vet. Clin. N. Am. Small Anim. Pract. 2003;33:473–489. doi: 10.1016/S0195-5616(03)00003-2. PubMed DOI

Ozaki K., Yamagami T., Nomura K., Narama I. Prognostic Significance of Surgical Margin, Ki-67 and Cyclin D1 Protein Expression in Grade II Canine Cutaneous Mast Cell Tumor. J. Vet. Med. Sci. 2007;69:1117–1121. doi: 10.1292/jvms.69.1117. PubMed DOI

Hahn K.A., King G.K., Carreras J.K. Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987–1998) J. Am. Vet. Med. Assoc. 2004;224:79–82. doi: 10.2460/javma.2004.224.79. PubMed DOI

Hayes A., Adams V., Smith K., Maglennon G., Murphy S. Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours. Vet. Comp. Oncol. 2007;5:168–176. doi: 10.1111/j.1476-5829.2007.00135.x. PubMed DOI

Pizzoni S., Sabattini S., Stefanello D., Dentini A., Ferrari R., Dacasto M., Giantin M., LaGanga P., Amati M., Tortorella G., et al. Features and prognostic impact of distant metastases in 45 dogs with de novo stage IV cutaneous mast cell tumours: A prospective study. Vet. Comp. Oncol. 2017;16:28–36. doi: 10.1111/vco.12306. PubMed DOI

Jaffe M.H., Hosgood G., Taylor H.W., Kerwin S.C., Hedlund C.S., Lopez M.K., Davidson J.R., Miller D.M., Paranjpe M. Immunohistochemical and Clinical Evaluation of p53 in Canine Cutaneous Mast Cell Tumors. Vet. Pathol. 2000;37:40–46. doi: 10.1354/vp.37-1-40. PubMed DOI

Cruz V.S., Borges J.C.A., Nepomuceno L.L., Gonçalves P.A.M., Prado Y.C.L., Bianchi C., Fioravanti M.C.S., Araújo E.G. Histological classification and expression of markers of canine mast cell tumors. Vet. World. 2020;13:1627–1637. doi: 10.14202/vetworld.2020.1627-1634. PubMed DOI PMC

Webster J.D., Yuzbasiyan-Gurkan V., Thamm D.H., Hamilton E., Kiupel M. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Vet. Res. 2008;4:32. doi: 10.1186/1746-6148-4-32. PubMed DOI PMC

Vascellari M., Giantin M., Capello K., Carminato A., Morello E.M., Vercelli A., Granato A., Buracco P., Dacasto M., Mutinelli F. Expression of Ki67, BCL-2, and COX-2 in Canine Cutaneous Mast Cell Tumors. Vet. Pathol. 2012;50:110–121. doi: 10.1177/0300985812447829. PubMed DOI

Casagrande T.A.C., Barros L.M.D.O., Fukumasu H., Cogliati B., Chaible L.M., Dagli M.L.Z., Matera J.M. The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours. Vet. Comp. Oncol. 2013;13:1–10. doi: 10.1111/vco.12010. PubMed DOI

Fonseca-Alves C.E., Bento D.D., Torres-Neto R., Werner J., Kitchell B., Laufer-Amorim R. Ki67/KIT double immunohistochemical staining in cutaneous mast cell tumors from Boxer dogs. Res. Vet. Sci. 2015;102:122–126. doi: 10.1016/j.rvsc.2015.08.007. PubMed DOI

Bergman P.J., Craft D.M., Newman S.J., Baer K., Camps-Palau M.A., McKnight J.A., Leibman N.F., Brenn S., Finora K., Hohenhaus A.E., et al. Correlation of histologic grading of canine mast cell tumors with Ki67/PCNA/AgNOR/c-Kit scores: 38 cases (2002-2003) Vet. Comp. Oncol. 2004;2:98. doi: 10.1111/j.1476-5810.2004.0045a.x. DOI

Barra C.N., Macedo B.M., Cadrobbi K.G., Pulz L.H., Huete G.C., Kleeb S.R., Xavier J.G., Catão-Dias J.L., Nishiya A.T., Fukumasu H., et al. Apoptotic intrinsic pathway proteins predict survival in canine cutaneous mast cell tumours. Vet. Comp. Oncol. 2017;16:E38–E44. doi: 10.1111/vco.12330. PubMed DOI

Melo S.R., Januário E.V., Zanuto E., De Castro Miranda B., Macedo T.R., Cogliati B., Matera J.M. Immunohistochemical Expression of Vascular Endothelial Growth Factor as a Prognostic Marker for Canine Mast Cell Tumor. Med. Top. Comp. Anim. 2021;43:100506. doi: 10.1016/j.tcam.2020.100506. PubMed DOI

Freytag J.O., Queiroz M.R., Govoni V.M., Pereira I.V.A., Pulz L.H., Strefezzi R.D.F., Queiroga F.L., Cogliati B. Prognostic value of immunohistochemical markers in canine cutaneous mast cell tumours: A systematic review and meta-analysis. Vet. Comp. Oncol. 2021;19:529–540. doi: 10.1111/vco.12692. PubMed DOI

Da Silva L., Fonseca-Alves C.E., Thompson J.J., Foster R.A., Wood G.A., Amorim R.L., Coomber B.L. Pilot assessment of vascular endothelial growth factor receptors and trafficking pathways in recurrent and metastatic canine subcutaneous mast cell tumours. Vet. Med. Sci. 2017;3:146–155. doi: 10.1002/vms3.66. PubMed DOI PMC

Kiupel M., Camus M. Diagnosis and Prognosis of Canine Cutaneous Mast Cell Tumors. Vet. Clin. North. Am. Small Anim. Pr. 2019;49:819–836. doi: 10.1016/j.cvsm.2019.04.002. PubMed DOI

Oliveira M.T., Campos M., Lamego L., Magalhães D., Menezes R., Oliveira R., Patanita F., Ferreira D.A. Canine and feline cutaneous mast cell tumour: A comprehensive review of treatments and outcomes. Top. Companion Anim. Med. 2020;41:100472. doi: 10.1016/j.tcam.2020.100472. PubMed DOI

Pratschke K.M., Atherton M.J., Sillito J.A., Lamm C.G. Evaluation of a modified proportional margins approach for surgical resection of mast cell tumors in dogs: 40 cases (2008–2012) J. Am. Vet. Med. Assoc. 2013;243:1436–1441. doi: 10.2460/javma.243.10.1436. PubMed DOI

Chu M.L., Hayes G.M., Henry J.G., Oblak M.L. Comparison of lateral surgical margins of up to two centimeters with margins of three centimeters for achieving tumor-free histologic margins following excision of grade I or II cutaneous mast cell tumors in dogs. J. Am. Vet. Med. Assoc. 2020;256:567–572. doi: 10.2460/javma.256.5.567. PubMed DOI

Saunders H., Thomson M.J., O’Connell K., Bridges J.P., Chau L. Evaluation of a modified proportional margin approach for complete surgical excision of canine cutaneous mast cell tumours and its association with clinical outcome. Vet. Comp. Oncol. 2020;19:604–615. doi: 10.1111/vco.12630. PubMed DOI

Selmic L.E., Ruple A. A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs. BMC Vet. Res. 2020;16:1–6. doi: 10.1186/s12917-019-2227-8. PubMed DOI PMC

Itoh T., Kojimoto A., Uchida K., Chambers J., Shii H. Long-term postsurgical outcomes of mast cell tumors resected with a margin proportional to the tumor diameter in 23 dogs. J. Vet. Med. Sci. 2021;83:230–233. doi: 10.1292/jvms.20-0281. PubMed DOI PMC

Simpson A.M., Ludwig L.L., Newman S.J., Bergman P.J., Hottinger H.A., Patnaik A.K. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. J. Am. Vet. Med. Assoc. 2004;224:236–240. doi: 10.2460/javma.2004.224.236. PubMed DOI

Donnelly L., Mullin C., Balko J., Goldschmidt M., Krick E., Hume C., Brown D.C., Sorenmo K. Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours. Vet. Comp. Oncol. 2013;13:70–76. doi: 10.1111/vco.12021. PubMed DOI

Ferrari R., Chiti L.E., Manfredi M., Ravasio G., De Zani D., Zani D.D., Giudice C., Gambini M., Dvm D.S. Biopsy of sentinel lymph nodes after injection of methylene blue and lymphoscintigraphic guidance in 30 dogs with mast cell tumors. Vet. Surg. 2020;49:1099–1108. doi: 10.1111/vsu.13483. DOI

Marconato L., Polton G., Stefanello D., Morello E., Ferrari R., Henriques J., Tortorella G., Benali S.L., Bergottini R., Vasconi M.E., et al. Therapeutic impact of regional lymphadenectomy in canine stage II cutaneous mast cell tumours. Vet. Comp. Oncol. 2018;16:580–589. doi: 10.1111/vco.12425. PubMed DOI

Fossum T.W. Cirurgia de pequenos animais. Elsevier; Centro Rio de Janeiro, Brazil: 2021. pp. 546–596.

Milovancev M., Townsend K.L., Tuohy J.L., Gorman E., Bracha S., Curran K.M., Russell D.S. Long-term outcomes of dogs undergoing surgical resection of mast cell tumors and soft tissue sarcomas: A prospective 2-year-long study. Vet. Surg. 2019;49:96–105. doi: 10.1111/vsu.13225. PubMed DOI

Karbe G.T., Davis E., Runge J.J., Brown D.C., Holt D.E. Evaluation of scar revision after inadequate primary excision of cutaneous mast cell tumors in 85 dogs (2000–2013) Vet. Surg. 2021;50:807–815. doi: 10.1111/vsu.13619. PubMed DOI

Mir L.M., Orlowski S., Belehradek J., Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur. J. Cancer Clin. Oncol. 1991;27:68–72. doi: 10.1016/0277-5379(91)90064-K. PubMed DOI

Mir L., Glass L., Serša G., Teissié J., Domenge C., Miklavčič D., Jaroszeski M., Orlowski S., Reintgen D., Rudolf Z., et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br. J. Cancer. 1998;77:2336–2342. doi: 10.1038/bjc.1998.388. PubMed DOI PMC

Tozon N., Tratar U.L., Znidar K., Sersa G., Teissie J., Cemazar M. Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats. J. Vis. Exp. 2016:e54760. doi: 10.3791/54760. PubMed DOI PMC

Mir L.M., Gehl J., Sersa G., Collins C.G., Garbay J.-R., Billard V., Geertsen P.F., Rudolf Z., O’Sullivan G.C., Marty M. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur. J. Cancer Suppl. 2006;4:14–25. doi: 10.1016/j.ejcsup.2006.08.003. DOI

Suzuki D.O., Anselmo J., de Oliveira K.D., Freytag J.O., Rangel M.M., Marques J.L., Ramos A. Numerical Model of Dog Mast Cell Tumor Treated by Electrochemotherapy. Artif. Organs. 2014;39:192–197. doi: 10.1111/aor.12333. PubMed DOI

Pintarelli G., Berkenbrock J., Rassele A., Rangel M., Suzuki D. Computer simulation of commercial conductive gels and their application to increase the safety of electrochemotherapy treatment. Med. Eng. Phys. 2019;74:99–105. doi: 10.1016/j.medengphy.2019.09.016. PubMed DOI

Gerlini G., Di Gennaro P., Borgognoni L. Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. OncoImmunology. 2012;1:1655–1657. doi: 10.4161/onci.21991. PubMed DOI PMC

Calvet C.Y., Famin D., André F.M., Mir L.M. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. OncoImmunology. 2014;3:e28131. doi: 10.4161/onci.28131. PubMed DOI PMC

Spugnini E.P., Baldi A. Electrochemotherapy in Veterinary Oncology. Vet. Clin. North. Am. Small Anim. Pr. 2019;49:967–979. doi: 10.1016/j.cvsm.2019.04.006. PubMed DOI

Spugnini E.P., Vincenzi B., Baldi F., Citro G., Baldi A. Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors. Anticancer Res. 2007;26:4585–4589. PubMed

Kodre V., Cemazar M., Pecar J., Sersa G., Cor A., Tozon N. Electrochemotherapy Compared to Surgery for Treatment of Canine Mast Cell Tumours. Vivo. 2009;23:55–62. PubMed

Spugnini E., Vincenzi B., Citro G., Dotsinsky I., Mudrov T., Baldi A. Evaluation of Cisplatin as an Electrochemotherapy Agent for the Treatment of Incompletely Excised Mast Cell Tumors in Dogs. J. Vet. Intern. Med. 2011;25:407–411. doi: 10.1111/j.1939-1676.2011.0678.x. PubMed DOI

Lowe R., Gavazza A., Impellizeri J.A., Soden D.M., Lubas G. The treatment of canine mast cell tumours with electrochemotherapy with or without surgical excision. Vet. Comp. Oncol. 2016;15:775–784. doi: 10.1111/vco.12217. PubMed DOI

Cemazar M., Avgustin J.A., Pavlin D., Sersa G., Poli A., Levacic A.K., Tesic N., Tratar U.L., Rak M., Tozon N. Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours. Vet. Comp. Oncol. 2016;15:641–654. doi: 10.1111/vco.12208. PubMed DOI

Salvadori C., Svara T., Rocchigiani G., Millanta F., Pavlin D., Cemazar M., Tratar U.L., Sersa G., Tozon N., Poli A. Effects of electrochemotherapy with cisplatin and peritumoral IL-12 gene electrotransfer on canine mast cell tumors: A histopathologic and immunohistochemical study. Radiol. Oncol. 2017;51:286–294. doi: 10.1515/raon-2017-0035. PubMed DOI PMC

Dobson J.M., Scase T.J. Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. J. Small Anim. Pr. 2007;48:424–431. doi: 10.1111/j.1748-5827.2007.00366.x. PubMed DOI

Dobson J., Cohen S., Gould S. Treatment of canine mast cell tumours with prednisolone and radiotherapy. Vet. Comp. Oncol. 2004;2:132–141. doi: 10.1111/j.1476-5810.2004.00048.x. PubMed DOI

Al-Sarraf R., Mauldin G.N., Patnaik A.K., Meleo K.A. A Prospective Study of Radiation Therapy for the Treatment of Grade 2 Mast Cell Tumors in 32 Dogs. J. Vet. Intern. Med. 1996;10:376–378. doi: 10.1111/j.1939-1676.1996.tb02084.x. PubMed DOI

Frimberger A., Moore A.S., LaRue S.M., Gliatto J.M., Bengtson A.E. Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases (1989-1993) J. Am. Anim. Hosp. Assoc. 1997;33:320–324. doi: 10.5326/15473317-33-4-320. PubMed DOI

LaDue T., Price G.S., Dodge R., Page R.L., Thrall D.E. Radiation therapy for incompletely resected canine mast cell tumors. Vet. Radiol. Ultrasound. 1998;39:57–62. doi: 10.1111/j.1740-8261.1998.tb00326.x. PubMed DOI

Poirier V.J., Adams W.M., Forrest L.J., Green E.M., Dubielzig R.R., Vail D.M. Radiation Therapy for Incompletely Excised Grade II Canine Mast Cell Tumors. J. Am. Anim. Hosp. Assoc. 2006;42:430–434. doi: 10.5326/0420430. PubMed DOI

Kry K.L., Boston S.E. Additional Local Therapy With Primary Re-Excision or Radiation Therapy Improves Survival and Local Control After Incomplete or Close Surgical Excision of Mast Cell Tumors in Dogs. Vet. Surg. 2014;43:182–189. doi: 10.1111/j.1532-950X.2014.12099.x. PubMed DOI

Chaffin K., Thrall D.E. Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis. Vet. Radiol. Ultrasound. 2002;43:392–395. doi: 10.1111/j.1740-8261.2002.tb01023.x. PubMed DOI

Lejeune A., Skorupski K., Frazier S., Vanhaezebrouck I., Rebhun R.B., Reilly C.M., Rodriguez C.O., Jr. Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999–2012) Vet. Comp. Oncol. 2013;13:267–280. doi: 10.1111/vco.12042. PubMed DOI PMC

Mendez S.E., Drobatz K.J., Duda L.E., White P., Kubicek L., Sorenmo K.U. Treating the locoregional lymph nodes with radiation and/or surgery significantly improves outcome in dogs with high-grade mast cell tumours. Vet. Comp. Oncol. 2019;18:239–246. doi: 10.1111/vco.12541. PubMed DOI

Carlsten K., London C.A., Haney S., Burnett R.C., Avery A.C., Thamm D. Multicenter Prospective Trial of Hypofractionated Radiation Treatment, Toceranib, and Prednisone for Measurable Canine Mast Cell Tumors. J. Vet. Intern. Med. 2011;26:135–141. doi: 10.1111/j.1939-1676.2011.00851.x. PubMed DOI PMC

Stiborova K., Treggiari E., Amores-Fuster I., Del Busto I., Killick D., Maddox T., Marrington M., Mason S.L., Blackwood L. Haematologic toxicity in dogs with mast cell tumours treated with vinblastine/prednisolone chemotherapy with/without radiotherapy. J. Small Anim. Pr. 2019;60:534–542. doi: 10.1111/jsap.13047. PubMed DOI

Boyle G.M., D’Souza M.M.A., Pierce C.J., Adams R.A., Cantor A.S., Johns J.P., Maslovskaya L., Gordon V.A., Reddell P., Parsons P. Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models. PLoS ONE. 2014;9:e108887. doi: 10.1371/journal.pone.0108887. PubMed DOI PMC

Miller J., Campbell J., Blum A., Reddell P., Gordon V., Schmidt P., Lowden S. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors. Front. Vet. Sci. 2019;6:106. doi: 10.3389/fvets.2019.00106. PubMed DOI PMC

Jones P.D., Campbell J.E., Brown G., Johannes C.M., Reddell P. Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate. J. Vet. Intern. Med. 2020;35:451–455. doi: 10.1111/jvim.16018. PubMed DOI PMC

Reddell P., De Ridder T.R., Morton J.M., Jones P.D., Campbell J.E., Brown G., Johannes C.M., Schmidt P.F., Gordon V. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate. J. Vet. Intern. Med. 2021;35:430–441. doi: 10.1111/jvim.16009. PubMed DOI PMC

De Ridder T.R., Campbell J.E., Burke-Schwarz C., Clegg D., Elliot E.L., Geller S., Kozak W., Pittenger S.T., Pruitt J.B., Riehl J., et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC -46) J. Vet. Intern. Med. 2020;35:415–429. doi: 10.1111/jvim.15806. PubMed DOI PMC

Brown G.K., Campbell J.E., Jones P.D., De Ridder T.R., Reddell P., Johannes C.M. Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate. Front. Vet. Sci. 2021;8 doi: 10.3389/fvets.2021.675804. PubMed DOI PMC

Burton J., Venable R., Vail D., Williams L., Clifford C., Axiak-Bechtel S., Avery A., Thamm D. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs. J. Vet. Intern. Med. 2015;29:1098–1104. doi: 10.1111/jvim.13573. PubMed DOI PMC

Stanclift R.M., Gilson S.D. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J. Am. Vet. Med. Assoc. 2008;232:53–62. doi: 10.2460/javma.232.1.53. PubMed DOI

Taylor F., Gear R., Hoather T., Dobson J. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. J. Small Anim. Pr. 2009;50:284–289. doi: 10.1111/j.1748-5827.2009.00732.x. PubMed DOI

Rassnick K.M., Bailey D.B., Russell D.S., Flory A.B., Kiselow M.A., Intile J., Malone E.K., Balkman C.E., Barnard S.M. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. Vet. Comp. Oncol. 2010;8:138–152. doi: 10.1111/j.1476-5829.2010.00217.x. PubMed DOI

Govier S.M. Principles of treatment for mast cell tumors. Clin. Tech. Small Anim. Pr. 2003;18:103–106. doi: 10.1053/svms.2003.36624. PubMed DOI

Horta R., LaValle G., Costa M., Moura L., Marcinowska A., Araújo R. Outcome of adjuvant chemotherapy with lomustine, vinblastine and chlorambucil on management of canine mast cell tumour of high to intermediate risk. Arq. Bras. Med. Vet. Zootec. 2017;69:1426–1436. doi: 10.1590/1678-4162-9172. DOI

Davies D.R., Wyatt K.M., Jardine J.E., Robertson I.D., Irwin P. Vinblastine and Prednisolone as Adjunctive Therapy for Canine Cutaneous Mast Cell Tumors. J. Am. Anim. Hosp. Assoc. 2004;40:124–130. doi: 10.5326/0400124. PubMed DOI

Trumel C., Bourgès-Abella N., Touron C., Lanore D., Geffré A., Diquelou A., Guelfi J.F., Braun J.P. Adverse Haematological Effects of Vinblastine, Prednisolone and Cimetidine Treatment: A Retrospective Study in Fourteen Dogs with Mast Cell Tumours. J. Vet. Med. Ser. A. 2005;52:275–279. doi: 10.1111/j.1439-0442.2005.00725.x. PubMed DOI

Thamm D., Turek M., Vail D. Outcome and Prognostic Factors Following Adjuvant Prednisone/Vinblastine Chemotherapy for High-Risk Canine Mast Cell Tumour: 61 Cases. J. Vet. Med. Sci. 2006;68:581–587. doi: 10.1292/jvms.68.581. PubMed DOI

Rosenthal R.C. Clinical applications of Vinca alkaloids. J. Am. Vet. Med. Assoc. 1981;179 PubMed

Golden D.L., Langston V. Uses of vincristine and vinblastine in dogs and cats. J. Am. Vet. Med. Assoc. 1988;193 PubMed

Rungsipipat A., Srichat W., Manachai N., Jearanai W., Wangnaitham S., Tangkawattana P., Tangkawattana S. Clinical evaluation of canine mast cell tumor treatment between combined vinblastine and prednisolone and single prednisolone. Comp. Clin. Path. 2009;18:77–84. doi: 10.1007/s00580-008-0758-7. DOI

Vickery K.R., Wilson H., Vail D.M., Thamm D.H. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Vet. Comp. Oncol. 2008;6:111–119. doi: 10.1111/j.1476-5829.2007.00147.x. PubMed DOI

Rassnick K., Bailey D., Flory A., Balkman C., Kiselow M., Intile J., Autio K. Efficacy of Vinblastine for Treatment of Canine Mast Cell Tumors. J. Vet. Intern. Med. 2008;22:1390–1396. doi: 10.1111/j.1939-1676.2008.0195.x. PubMed DOI

Varela J.C.S., Pecceu E., Handel I., Lawrence J. Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours. Vet. Med. Sci. 2016;2:266–280. doi: 10.1002/vms3.42. PubMed DOI PMC

Bailey D., Rassnick K., Kristal O., Chretin J., Balkman C. Phase I Dose Escalation of Single-Agent Vinblastine in Dogs. J. Vet. Intern. Med. 2008;22:1397–1402. doi: 10.1111/j.1939-1676.2008.0196.x. PubMed DOI

Kluthcovsky L.C., Firmo B.F., Cassino P.C., De Nardi A.B., Castro J.L.C., Halila R.L., Filho J.R.E. Comparison of Two Different Vinblastine Dosages for Treatment of Cutaneous Mast Cell Tumor in Dogs. Acta Sci. Vet. 2020;48 doi: 10.22456/1679-9216.101997. DOI

Hosoya K., Kisseberth W.C., Alvarez F.J., Lara-Garcia A., Beamer G.L., Stromberg P.C., Couto C.G. Adjuvant CCNU (Lomustine) and Prednisone Chemotherapy for Dogs With Incompletely Excised Grade 2 Mast Cell Tumors. J. Am. Anim. Hosp. Assoc. 2009;45:14–18. doi: 10.5326/0450014. PubMed DOI

Hay J.K., Larson V.S. Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors. Can. Vet. J. = La Rev. Vet. Can. 2019;60:1326–1330. PubMed PMC

Cooper M., Tsai X., Bennett P. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Vet. Comp. Oncol. 2009;7:196–206. doi: 10.1111/j.1476-5829.2009.00190.x. PubMed DOI

Teng S.-P., Hsu W.-L., Chiu C.-Y., Wong M.-L., Chang S.-C. Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment. Vet. J. 2012;193:551–556. doi: 10.1016/j.tvjl.2012.01.033. PubMed DOI

Linde K.J., Stockdale S.L., Mison M.B., Perry J.A. The effect of prednisone on histologic and gross characteristics in canine mast cell tumors. Can. Vet. J. = La Rev. Vet. Can. 2021;62:45–50. PubMed PMC

Horta R.D.S., Lavalle G.E., Monteiro L.N., dos Reis F.A., Costa M.D.P., Giuliano A., Cassali G.D., Dobson J. Evaluation of Histological, Immunohistochemical, Clinical and Genetic Prognostic Factors Associated with the Response of Canine Mast Cell Tumours to Glucocorticotherapy. J. Comp. Pathol. 2018;165:72–81. doi: 10.1016/j.jcpa.2018.10.001. PubMed DOI

Ginn P.E., Fox L.E., Brower J.C., Gaskin A., Kurzman I.D., Kubilis P.S. Immunohistochemical Detection of p53 Tumor-Suppressor Protein is a Poor Indicator of Prognosis for Canine Cutaneous Mast Cell Tumors. Vet. Pathol. 2000;37:33–39. doi: 10.1354/vp.37-1-33. PubMed DOI

Miyoshi N., Tojo E., Oishi A., Fujiki M., Misumi K., Sakamoto H., Kameyama K., Shimizu T., Yasuda N. Immunohistochemical detection of P-glycoprotein (PGP) and multidrug resistance-associated protein (MRP) in canine cutaneous mast cell tumors. J. Vet. Med. Sci. 2002;64:531–533. doi: 10.1292/jvms.64.531. PubMed DOI

Nakaichi M., Takeshita Y., Okuda M., Nakamoto Y., Itamoto K., Une S., Sasaki N., Kadosawa T., Takahashi T., Taura Y. Expression of the MDR1 Gene and P-Glycoprotein in Canine Mast Cell Tumor Cell Lines. J. Vet. Med. Sci. 2007;69:111–115. doi: 10.1292/jvms.69.111. PubMed DOI

Colleoni M., Rocca A., Sandri M.T., Zorzino L., Masci G., Nolè F., Peruzzotti G., Robertson C., Orlando L., Cinieri S., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 2002;13:73–80. doi: 10.1093/annonc/mdf013. PubMed DOI

Pasquier E., Kavallaris M., André N. Metronomic chemotherapy: New rationale for new directions. Nat. Rev. Clin. Oncol. 2010;7:455–465. doi: 10.1038/nrclinonc.2010.82. PubMed DOI

Tripp C., Fidel J., Anderson C., Patrick M., Pratt C., Sellon R., Bryan J. Tolerability of Metronomic Administration of Lomustine in Dogs with Cancer. J. Vet. Intern. Med. 2011;25:278–284. doi: 10.1111/j.1939-1676.2011.0684.x. PubMed DOI

Leach T.N., Childress M.O., Greene S.N., Mohamed A.S., Moore G.E., Schrempp D.R., Lahrman S.R., Knapp D.W. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer. Vet. Comp. Oncol. 2011;10:102–112. doi: 10.1111/j.1476-5829.2011.00280.x. PubMed DOI

Gaspar T.B., Henriques J., Marconato L., Queiroga F.L. The use of low-dose metronomic chemotherapy in dogs-insight into a modern cancer field. Vet. Comp. Oncol. 2017;16:2–11. doi: 10.1111/vco.12309. PubMed DOI

Thamm D.H., Mauldin E.A., Vail D.M. Prednisone and vinblastine chemotherapy for canine mast cell tumor—41 cases (1992–1997) J. Vet. Intern. Med. 1999;13:491–497. PubMed

Camps-Palau M.A., Leibman N.F., Elmslie R., Lana S.E., Plaza S., McKnight J.A., Risbon R., Bergman P.J. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997?2004) Vet. Comp. Oncol. 2007;5:156–167. doi: 10.1111/j.1476-5829.2006.00125.x. PubMed DOI

Rassnick K.M., Moore A.S., Williams L.E., London C.A., Kintzer P.P., Engler S.J., Cotter S.M. Treatment of Canine Mast Cell Tumors with CCNU (Lomustine) J. Vet. Intern. Med. 1999;13:601–605. doi: 10.1111/j.1939-1676.1999.tb02217.x. PubMed DOI

Olsen J.A., Thomson M., O’Connell K., Wyatt K. Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs. Vet. Med. Sci. 2018;4:237–251. doi: 10.1002/vms3.106. PubMed DOI PMC

London C.A. Tyrosine Kinase Inhibitors in Veterinary Medicine. Top. Companion Anim. Med. 2009;24:106–112. doi: 10.1053/j.tcam.2009.02.002. PubMed DOI

Soria J., Massard C., Magné N., Bader T., Mansfield C., Blay J., Bui B., Moussy A., Hermine O., Armand J. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur. J. Cancer. 2009;45:2333–2341. doi: 10.1016/j.ejca.2009.05.010. PubMed DOI

Ogilvie G., Ahn A. Masitinib–the efficacy of targeted therapy in veterinary medicine. Vet. Cancer Soc. Newsl. Summer. 2010;34:6–11.

Hahn K.A., Legendre A.M., Shaw N.G., Phillips B., Ogilvie G.K., Prescott D.M., Atwater S.W., Carreras J.K., Lana S.E., LaDue T., et al. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am. J. Vet. Res. 2010;71:1354–1361. doi: 10.2460/ajvr.71.11.1354. PubMed DOI

London C.A., Hannah A.L., Zadovoskaya R., Chien M.B., Kollias-Baker C., Rosenberg M., Downing S., Post G., Boucher J., Shenoy N., et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin. Cancer Res. 2003;9:2755–2768. PubMed

Weishaar K., Ehrhart E., Avery A., Charles J., Elmslie R., Vail D., London C., Clifford C., Eickhoff J., Thamm D. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine. J. Vet. Intern. Med. 2017;32:394–405. doi: 10.1111/jvim.14889. PubMed DOI PMC

Mitchell L., Thamm D., Biller B. Clinical and Immunomodulatory Effects of Toceranib Combined with Low-Dose Cyclophosphamide in Dogs with Cancer. J. Vet. Intern. Med. 2012;26:355–362. doi: 10.1111/j.1939-1676.2011.00883.x. PubMed DOI

Amagai Y., Tanaka A., Jung K., Matsuda A., Oida K., Nishikawa S., Jang H., Ishizaka S., Matsuda H. Production of stem cell factor in canine mast cell tumors. Res. Vet. Sci. 2013;96:124–126. doi: 10.1016/j.rvsc.2013.10.014. PubMed DOI

Horta R.D.S., Giuliano A., LaValle G.E., Costa M.D.P., De Ara�Jo R., Constantino-Casas F., Dobson J.M. Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors. Oncol. Lett. 2017;15:129–136. doi: 10.3892/ol.2017.7323. PubMed DOI PMC

Smrkovski O.A., Essick L., Rohrbach B.W., Legendre A.M. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours. Vet. Comp. Oncol. 2013;13:314–321. doi: 10.1111/vco.12053. PubMed DOI

London C., Mathie T., Stingle N., Clifford C., Haney S., Klein M.K., Beaver L., Vickery K., Vail D.M., Hershey B., et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours. Vet. Comp. Oncol. 2012;10:194–205. doi: 10.1111/j.1476-5829.2011.00275.x. PubMed DOI PMC

Grant J., North S., Lanore D. Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours. J. Small Anim. Pr. 2016;57:283–290. doi: 10.1111/jsap.12480. PubMed DOI

Robat C., London C., Bunting L., McCartan L., Stingle N., Selting K., Kurzman I., Vail D.M. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: A phase I dose-finding study. Vet. Comp. Oncol. 2011;10:174–183. doi: 10.1111/j.1476-5829.2011.00261.x. PubMed DOI PMC

Pan X., Tsimbas K., Kurzman I.D., Vail D.M. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia®) in tumour-bearing dogs: A phase I dose-finding study. Vet. Comp. Oncol. 2014;14:202–209. doi: 10.1111/vco.12091. PubMed DOI

Bavcar S., de Vos J., Kessler M., de Fornel P., Buracco P., Murphy S., Hirschberger J., Argyle D. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study. Vet. J. 2017;224:1–6. doi: 10.1016/j.tvjl.2017.04.010. PubMed DOI

Gieger T., Northrup N., Wall M. Clinical management of mast cell tumors in dogs. Compend. Contin. Educ. Pract. Vet. 2005;27:56–68.

Peters L.J., Kovacic J.P. Histamine: Metabolism, physiology, and pathophysiology with applications in veterinary medicine. J. Vet. Emerg. Crit. Care. 2009;19:311–328. doi: 10.1111/j.1476-4431.2009.00434.x. PubMed DOI

Guedes A.G., Rudé E.P., Rider M.A. Evaluation of histamine release during constant rate infusion of morphine in dogs. Vet. Anaesth. Analg. 2006;33:28–35. doi: 10.1111/j.1467-2995.2005.00218.x. PubMed DOI

O’Keefe D.A. Canine Mast Cell Tumors. Vet. Clin. North. Am. Small Anim. Pr. 1990;20:1105–1115. doi: 10.1016/S0195-5616(90)50087-X. PubMed DOI

Pavlin D., Cemazar M., Cör A., Sersa G., Pogacnik A., Tozon N. Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol. Oncol. 2011;45:31–39. doi: 10.2478/v10019-010-0041-9. PubMed DOI PMC

Lin T.-Y., Fenger J., Murahari S., Bear M.D., Kulp S.K., Wang D., Chen C.-S., Kisseberth W.C., London C.A. AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood. 2010;115:4217–4225. doi: 10.1182/blood-2009-07-231985. PubMed DOI PMC

Nagamine M.K., Sanches D.S., Pinello K.C., Torres L.N., Mennecier G., Latorre A.O., Fukumasu H., Dagli M.L.Z. In vitro inhibitory effect of trichostatin A on canine grade 3 mast cell tumor. Vet. Res. Commun. 2011;35:391–399. doi: 10.1007/s11259-011-9474-x. PubMed DOI

Keller A., Wingelhofer B., Peter B., Bauer K., Berger D., Gamperl S., Reifinger M., Cerny-Reiterer S., Moriggl R., Willmann M., et al. The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. Vet. Comp. Oncol. 2017;16:55–68. doi: 10.1111/vco.12311. PubMed DOI PMC

Cletzer E., Klahn S., Dervisis N., LeRoith T. Identification of the JAK-STAT pathway in canine splenic hemangiosarcoma, thyroid carcinoma, mast cell tumor, and anal sac adenocarcinoma. Vet. Immunol. Immunopathol. 2019;220:109996. doi: 10.1016/j.vetimm.2019.109996. PubMed DOI